U.S. stock night trading volatility: Trump's remarks triggered fluctuations in cannabis stocks, Canopy Growth rose 8.11% in after-hours trading

U.S. Stock Night Market Movements Canopy Growth rose 8.11% in the night market. Based on recent key news: On December 19, U.S. President Trump stated that the cannabis order is not law, which led to mixed movements in cannabis stocks, with Canopy Growth rising 4.9%. Source: Zhitong Finance On December 19, analysts rated Canopy Growth as a sell, believing its business is relatively weak despite policy progress. Source: MarketBeat On December 20, the executive order enhanced the long-term investment outlook for U.S. cannabis stocks, but the rescheduling extended the timeline, giving investors time to assess the fundamentals. Source: Wall Street Insight on cannabis industry policy changes, investors need to assess cautiously. Stocks with High Trading Volume in the Industry Eli Lilly fell 0.41% in the night market. Based on recent key news: On December 20, Eli Lilly plans to launch oral olipudine, expected to be available by 2026. The convenience and low cost of oral medications may attract more patients, driving market demand and enhancing sales potential. On December 19, BMO Capital analysts maintained a buy rating on Eli Lilly, with a target price of $1200. The analyst consensus is a strong buy, indicating market confidence in Eli Lilly's future performance. On December 19, Eli Lilly announced positive Phase III data for Orforglipron, showing that the oral medication helps patients maintain weight loss, reducing future income risks and improving financial health scores. The obesity drug market has huge potential, with expanded insurance coverage. Pfizer rose 0.64% in the night market. Based on recent key news: On December 20, the Trump administration requested pharmaceutical companies to lower drug prices in exchange for tariff exemptions and other benefits. This move may impact Pfizer's profitability, leading to stock price fluctuations. Source: Zhitong Finance On December 20, analysts maintained a buy rating on Pfizer, believing its cash flow and diversified product portfolio support long-term growth. This rating may boost investor confidence and drive stock price increases. Source: Zhitong Finance On December 19, Pfizer was recognized in the Pharmaceutical Technology Excellence Awards, showcasing its expansion capabilities in integrated manufacturing. This may enhance market confidence in its business expansion. Source: Zhitong Finance, the pharmaceutical industry faces policy pressures, focus on long-term growth potential. Novo Nordisk rose 0.15% in the night market. Based on recent key news: On December 19, Novo Nordisk submitted a new drug application for CagriSema to the FDA, aiming to treat obesity or overweight by reducing calorie intake and increasing physical activity. This application marks an important milestone in obesity treatment, potentially driving stock price increases. Source: Benzinga On December 20, Novo Nordisk's oral semaglutide is expected to receive approval by the end of the year, and the convenience and low cost of oral medications may attract more patients, driving market demand. Source: Barron's On December 19th, analysts rated Novo Nordisk as a hold, believing that five other stocks have more investment value, which may put pressure on the stock price. Source: MarketBeat The demand for obesity drugs is rising, with policy support